---
title: "LakeShore Biopharma Co., Ltd (LSBCF.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/LSBCF.US.md"
symbol: "LSBCF.US"
name: "LakeShore Biopharma Co., Ltd"
industry: "Biotechnology"
datetime: "2026-05-21T17:38:36.483Z"
locales:
  - [en](https://longbridge.com/en/quote/LSBCF.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/LSBCF.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/LSBCF.US.md)
---

# LakeShore Biopharma Co., Ltd (LSBCF.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.lakeshorebio.com](https://www.lakeshorebio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:18.000Z

**Overall: C (0.55)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 178 / 385 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 7.41% |  |
| Net Profit YoY | 76.90% |  |
| P/B Ratio | 0.02 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1524869.64 |  |
| Revenue | 85290264.24 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -18.43% | E |
| Profit Margin | -16.26% | D |
| Gross Margin | 82.47% | A |
| Revenue YoY | 7.41% | C |
| Net Profit YoY | 76.90% | A |
| Total Assets YoY | -10.15% | E |
| Net Assets YoY | -15.11% | E |
| Cash Flow Margin | 121.00% | B |
| OCF YoY | 7.41% | C |
| Turnover | 0.43 | C |
| Gearing Ratio | 63.46% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - LakeShore Biopharma Co., Ltd",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "7.41%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "76.90%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.02",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "1524869.64",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "85290264.24",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-18.43%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-16.26%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "82.47%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "7.41%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "76.90%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-10.15%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-15.11%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "121.00%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "7.41%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.43",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "63.46%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.11 | 77/385 | - | - | - |
| PB | 0.02 | 3/385 | 0.50 | 0.44 | 0.03 |
| PS (TTM) | 0.02 | 2/385 | 0.41 | 0.36 | 0.02 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/LSBCF.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/LSBCF.US/norm.md)
- [Related News](https://longbridge.com/en/quote/LSBCF.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/LSBCF.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**